ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.680,20
-0,25%
S&P 500
5.316,47
-0,09%
Dow Jones
39.794,64
-0,20%
Euro vs US Dollar
1,08412
-0,13%
Bitcoin
70.484,36
0,50%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Context Therapeutics Inc (CNTX)

  7. Context Therapeutics Inc (CNTX) News

CNTX

Context Therapeutics (CNTX)

Context Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:CNTX
DatumZeitQuelleÜberschriftSymbolFirma
16/05/202422h01Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:CNTXContext Therapeutics Inc
10/05/202422h00Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:CNTXContext Therapeutics Inc
08/05/202422h06GlobeNewswire Inc.Context Therapeutics Reports First Quarter 2024 Operating and Financial ResultsNASDAQ:CNTXContext Therapeutics Inc
08/05/202422h03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CNTXContext Therapeutics Inc
02/05/202413h31GlobeNewswire Inc.Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76NASDAQ:CNTXContext Therapeutics Inc
02/05/202413h30GlobeNewswire Inc.Context Therapeutics Announces $100 Million Private PlacementNASDAQ:CNTXContext Therapeutics Inc
01/04/202413h30GlobeNewswire Inc.Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive CancersNASDAQ:CNTXContext Therapeutics Inc
21/03/202412h43GlobeNewswire Inc.Context Therapeutics Reports Full Year 2023 Operating and Financial ResultsNASDAQ:CNTXContext Therapeutics Inc
06/03/202413h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CNTXContext Therapeutics Inc
07/02/202422h24Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CNTXContext Therapeutics Inc
09/11/202322h15GlobeNewswire Inc.Context Therapeutics Reports Third Quarter 2023 Operating and Financial ResultsNASDAQ:CNTXContext Therapeutics Inc
09/11/202322h04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CNTXContext Therapeutics Inc
31/10/202314h04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CNTXContext Therapeutics Inc
31/10/202314h00GlobeNewswire Inc.Context Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76NASDAQ:CNTXContext Therapeutics Inc
27/09/202315h00GlobeNewswire Inc.Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual MeetingNASDAQ:CNTXContext Therapeutics Inc
09/08/202322h10GlobeNewswire Inc.Context Therapeutics Reports Second Quarter 2023 Operating and Financial ResultsNASDAQ:CNTXContext Therapeutics Inc
09/08/202322h04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CNTXContext Therapeutics Inc
07/08/202314h11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CNTXContext Therapeutics Inc
01/08/202313h30GlobeNewswire Inc.Context Therapeutics to Participate in Two August 2023 Investor ConferencesNASDAQ:CNTXContext Therapeutics Inc
20/06/202314h36Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CNTXContext Therapeutics Inc
31/05/202322h53Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CNTXContext Therapeutics Inc
10/05/202322h39GlobeNewswire Inc.Context Therapeutics Reports First Quarter 2023 Operating and Financial ResultsNASDAQ:CNTXContext Therapeutics Inc
03/04/202313h30GlobeNewswire Inc.Context Therapeutics to Participate in Two April 2023 Investor ConferencesNASDAQ:CNTXContext Therapeutics Inc
27/03/202322h04Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:CNTXContext Therapeutics Inc
22/03/202322h10Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CNTXContext Therapeutics Inc
22/03/202322h08GlobeNewswire Inc.Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline UpdatesNASDAQ:CNTXContext Therapeutics Inc
15/03/202312h30GlobeNewswire Inc.Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023NASDAQ:CNTXContext Therapeutics Inc
14/02/202323h26Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CNTXContext Therapeutics Inc
14/02/202323h26Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CNTXContext Therapeutics Inc
14/02/202323h25Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CNTXContext Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:CNTX

Kürzlich von Ihnen besucht

TG
D7G
Nel ASA
CCOM
US100
US Tech 100
USOTC
ADDYY
Adidas (QX)
AMEX
SPY
SPDR S&P 500
TG
DBK
Deutsche Bank
TG
ALV
Allianz
TG
TUI1
Tui
NYSE
JPM
JP Morgan Chase
FX
EURUSD
Euro vs US Dollar
TG
MBG
MercedesBenz
COIN
SOLUSD
Solana
NYSE
NKE
Nike
TG
BAYN
Bayer
DBI
MDAX
MDAX
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten